|
Steatohepatitis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our results provided direct evidence for a novel, PPARα-mediated mechanism responsible for the beneficial effects of RSV on hepatic steatosis.
|
31173696 |
2020 |
|
Steatohepatitis
|
0.400 |
Biomarker
|
disease |
BEFREE |
We used real-time polymerase chain reaction (RT-PCR) analysis to evaluate the hepatic and intestinal expression level of all genes studied (TLR2, TLR4, TLR9, LXRα, SREBP1C, ACC1, FAS, PPARα, CPT1α, CROT, SREBP2, ABCA1, ABCG1 and FXR in the liver; TLR2, TLR4, TLR5, TLR9, GLP-1R, DPP-4, FXR and PPARɣ in the jejunum) in 82 women with MO with normal liver histology (NL, n = 29), SS (n = 32), and NASH (n = 21).
|
31388096 |
2020 |
|
Steatohepatitis
|
0.400 |
PosttranslationalModification
|
disease |
BEFREE |
Paternal hyperglycemia induces transgenerational inheritance of susceptibility to hepatic steatosis in rats involving altered methylation on Pparα promoter.
|
30404040 |
2019 |
|
Steatohepatitis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Elevated lipolysis in adipose tissue by doxorubicin via PPARα activation associated with hepatic steatosis and insulin resistance.
|
30452912 |
2019 |
|
Steatohepatitis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
ALR depletion from primary hepatocytes increased oxidative stress, miR-540 expression, and steatosis and down-regulated PPARα, ACOX1, PMP70, and CPT1a expression.
|
30540918 |
2019 |
|
Steatohepatitis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In conclusion, these results suggest that MO has protective potential against hyperlipidemia and steatosis, and the potential mechanism may have a close relation with activation of PPARα and inhibition of SREBP-1c.
|
30937936 |
2019 |
|
Steatohepatitis
|
0.400 |
Biomarker
|
disease |
BEFREE |
PPARα contributes to the CYP2A5 protective effects on fatty liver but it opposes to the protective effects on obesity.
|
29568101 |
2019 |
|
Steatohepatitis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Some of the natural AR inhibitors have been reported to attenuate hepatic steatosis through the regulation of PPARα-mediated fatty acid oxidation.
|
31589122 |
2019 |
|
Steatohepatitis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Sensitivity to steatohepatitis due to WZ administration correlated significantly with alterations in the expression of PPAR-α/γ, as well as the NF-κB signalling pathway.
|
30522014 |
2019 |
|
Steatohepatitis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In addition, the CinLac group showed increased hepatic triacylglycerol content (P = 0.049) and a mild steatosis (P = 0.001), accompanied by reduced PPARα mRNA expression (P = 0.005).
|
30276593 |
2019 |
|
Steatohepatitis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, MG clearly alleviated serum TG and total cholesterol release; upregulated AKT, AMPK, and PPARα expression; suppressed SREBP-1c generation; and alleviated hepatic steatosis and dyslipidemia in Ty-induced hyperlipidemia mice.
|
29467759 |
2018 |
|
Steatohepatitis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Since human steatohepatitis (both the alcoholic and non-alcoholic type) is characterized by reduced expression of PPARα and disturbed lipid metabolism we investigated the role of this ligand-activated receptor in the development of DDC-induced liver injury.
|
30154499 |
2018 |
|
Steatohepatitis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Nuciferine improved lipid profile and attenuated hepatic steatosis in HFD/STZ-induced diabetic mice by activating the PPARα/PGC1α pathway.
|
30129056 |
2018 |
|
Steatohepatitis
|
0.400 |
Biomarker
|
disease |
BEFREE |
These findings indicate new mechanisms of action for both PPARα and PPARγ, and new potential treatment options for nonalcoholic fatty liver disease (NAFLD) and steatosis.This article has an associated First Person interview with the first author of the paper.
|
30171034 |
2018 |
|
Steatohepatitis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In this study, we showed that the overexpression of PIK3R3 promoted hepatic fatty acid oxidation via PIK3R3-induced expression of PPARα, thus improving the fatty liver phenotype in high-fat diet (HFD)-induced mice.
|
29350678 |
2018 |
|
Steatohepatitis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Acute fasting activated PPARA and led to steatosis, whereas EODF protected against fasting-induced hepatic steatosis without affecting PPARA signaling.
|
29146411 |
2018 |
|
Steatohepatitis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
After normalization of the steatosis-related circRNA by expression vector, analysis of miR-34a activity, peroxisome proliferator-activated receptor (PPAR)α level, and expression of downstream genes were carried out so as to reveal its impact on the miR-34a/PPARα regulatory system.
|
29391755 |
2018 |
|
Steatohepatitis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Aged and Zmpste24-deficient livers share several features, including nuclear lamina abnormalities, increased Foxa2 binding, de-repression of PPAR- and LXR-dependent gene expression, and fatty liver.
|
29484800 |
2018 |
|
Steatohepatitis
|
0.400 |
Biomarker
|
disease |
BEFREE |
During the development of hepatic steatosis (8-16 weeks), PPARα was activated as indicated by its target genes as well as the elevated peroxisomal acyl-CoA oxidase activity.
|
30120929 |
2018 |
|
Steatohepatitis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our results suggest that disorders of the PPAR and p53 signaling pathways may be involved in steatohepatitis development and in the therapeutic mechanism of the SSB extract treatment; these observations shed new light on possible treatment of steatohepatitis.
|
29855491 |
2018 |
|
Steatohepatitis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
IRD induced liver steatosis and oxidative stress (higher levels of protein oxidation and lipid peroxidation with glutathione depletion), mitochondrial dysfunction (decreased citrate synthase and complex I and II activities) and loss of polyunsaturated fatty acids (PUFAs), with a drastic enhancement in the sterol regulatory element-binding protein-1c (SREBP-1c)/peroxisome proliferator-activated receptor-α (PPAR-α) ratio upregulating the expression of lipogenic enzymes (acetyl-CoA carboxylase, fatty acid (FA) synthase and stearoyl desaturase 2) and downregulating those involved in FA oxidation (carnitine palmitoyl transferase and acyl-CoA oxidase) over values in the CD group.
|
30153476 |
2018 |
|
Steatohepatitis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Hepatic miR-141 and miR-200c RNA levels were highly induced in human patients with NASH fatty liver and in WT MCD mice. miR-141/200c-/- MCD mice had reduced liver weights and triglyceride (TG) levels, which was associated with increased microsomal TG transfer protein (MTTP) and PPARα but reduced SREBP1c and FAS expression.
|
29093267 |
2017 |
|
Steatohepatitis
|
0.400 |
Biomarker
|
disease |
BEFREE |
The results showed that WEPE could significantly decrease body weight, peritoneal fat and epididymal fat, enhance the antioxidant enzyme activities, and improve steatosis through elevating adiponectin in adipocytes and PPAR-α in the liver as well as lowering SREBP-1c in the liver of rats fed with a high fat diet (HFD).
|
28128372 |
2017 |
|
Steatohepatitis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Liver steatosis was reduced by RBEE supplementation of LFD (1% RBEE) and HFD (1 and 5% RBEE) and nuclear peroxisome proliferator-activated receptor-α expression upregulated in the HDF 5% RBEE group.
|
28359358 |
2017 |
|
Steatohepatitis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Apelin protects against liver X receptor-mediated steatosis through AMPK and PPARα in human and mouse hepatocytes.
|
28821440 |
2017 |